Role of Gnrh agonist in supporting pregnancy after frozen embryo transfer.

Effectiveness of single dose GnRH agonist for luteal phase support in women with previous assisted reproductive technology (ART) failure undergoing frozen embryo transfer cycle: A randomized controlled trial - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057487

Enrollment

190

Registered

2023-09-12

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N979- Female infertility, unspecified

Interventions

Intervention1: Modified luteal support: Participants in this study group will receive a single dose of GnRH agonist (1 mg leuprolide acetate, subcutaneous) on day 6 of start of progesterone (p+6th) in

Eligibility

Inclusion criteria

Inclusion criteria: More than or equal to 1 previous ART failure (frozen embryo transfers with a negative outcome) Planned for hormone replacement cycle (HRC) or downregulated HRC frozen embryo transfer (FET)

Exclusion criteria

Exclusion criteria: Uterine anomalies (bicornuate/unicornuate uterus diagnosed by 2D/3D ultrasound) Evidence of hydrosalpinx by ultrasound Natural /modified stimulated cycles Known drug allergy

Design outcomes

Primary

Measure	Time frame
Clinical pregnancy rate per woman randomizedTimepoint: at the end of 6 weeks post recruitment	—

Secondary

Measure	Time frame
Miscarriage rate per clinical pregnancy Timepoint: up to 6 months post recruitment;Implantation rate per woman randomizedTimepoint: at 6 weeks post recruitment;Ongoing pregnancy rate per woman randomizedTimepoint: at 3 months post recruitment;Live birth rate per woman randomizedTimepoint: upto 10 months post recruitment;Adverse drug reactions per woman randomizedTimepoint: up to 3 months post recruitment	—

Measure

Time frame

Miscarriage rate per clinical pregnancy Timepoint: up to 6 months post recruitment;Implantation rate per woman randomizedTimepoint: at 6 weeks post recruitment;Ongoing pregnancy rate per woman randomizedTimepoint: at 3 months post recruitment;Live birth rate per woman randomizedTimepoint: upto 10 months post recruitment;Adverse drug reactions per woman randomizedTimepoint: up to 3 months post recruitment

—

Countries

India

Contacts

Public ContactDr Treasa Joseph

Christian Medical College and Hospital

treazzz@gmail.com9496368538

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026